Korean Journal of Psychosomatic Medicine (정신신체의학)

Korean Psychosomatic Society (한국정신신체의학회)
권호 표지
DOI QR코드

DOI QR Code

The Effect of Second-Generation Antipsychotics Administration for 1-Year on the Platelet Activities in Patients With Schizophrenia: Retrospective Study

조현병 환자에서 1년간의 2세대 항정신병약물 지속적 투여가 혈소판 활성도에 미치는 영향: 후향적 연구

  • Yoon-Seok, Oh (Department of Psychiatry, College of Medicine, Konyang University) ;
  • Jong Wook, Lee (Konyang University Myunggok Medical Research Institute) ;
  • Hong-Seok, Oh (Department of Psychiatry, College of Medicine, Konyang University) ;
  • Seung-Jun, Kim (Department of Psychiatry, College of Medicine, Konyang University) ;
  • Na-Hyun, Lee (Department of Psychiatry, College of Medicine, Konyang University) ;
  • Woo Young, Im (Department of Psychiatry, College of Medicine, Konyang University) ;
  • Ji-Woong, Kim (Department of Psychiatry, College of Medicine, Konyang University)
  • 오윤석 (건양대학교 의과대학 정신건강의학과교실) ;
  • 이종욱 (건양대학교 명곡의과학연구소) ;
  • 오홍석 (건양대학교 의과대학 정신건강의학과교실) ;
  • 김승준 (건양대학교 의과대학 정신건강의학과교실) ;
  • 이나현 (건양대학교 의과대학 정신건강의학과교실) ;
  • 임우영 (건양대학교 의과대학 정신건강의학과교실) ;
  • 김지웅 (건양대학교 의과대학 정신건강의학과교실)
  • Received : 2022.08.02
  • Accepted : 2022.09.16
  • Published : 2022.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : This study was conducted to investigate the effect of 1-year administration of second-generation antipsychotics (SGAs) on the platelet activity in patients with schizophrenia through a retrospective review of the medical records. Methods : The mean platelet component (MPC) value was used as an index of the platelet activity. The included subjects (N=24) were the patients who were confirmed to have taken SGAs continuously for one year after the first MPC measurement had been performed. The change of MPC was verified through a paired sample t-test. Results : The result revealed that the mean MPC value was significantly decreased from 26.5±1.4 g/dL to 25.6±1.8 g/dL after 1-year administration of SGAs from the time of the first MPC measurement. Conclusions : This study suggests that 1-year administration of SGAs may be related with increased platelet activity, and that close monitoring for risks such as cerebrovascular/cardiovascular or thromboembolic diseases may be necessary during SGAs treatment in clinical practice.

연구목적 본 연구는 후향적 의무기록 검토를 통해 조현병 환자에서 1년간의 2세대 항정신병약물 투여가 혈소판 활성에 미치는 영향을 알아보기 위해 시행되었다. 방 법 혈소판 활성의 지표로는 평균혈소판요소(mean platelet component, MPC) 값을 이용하였다. 첫 평균혈소판요소 측정 이후 1년간 지속적으로 2세대 항정신병약물을 꾸준히 복용한 것으로 확인된 조현병 환자 총 24명을 대상으로, 평균혈소판요소의 변화를 대응 표본 t 검정을 통해 검증하였다. 결 과 첫 측정 시 및 1년간의 2세대 항정신병약물 투여 후의 평균혈소판요소 값은 각각 26.5±1.4 g/dL와 25.6±1.8 g/dL로, 1년간의 약물 복용 후 유의하게 평균혈소판요소 값이 감소하였다. 결 론 본 연구는 1년간의 2세대 항정신병약물 투여 시 혈소판 활성이 증가될 수 있음을 시사하며, 임상 진료 시 이와 관련될 수 있는 심뇌혈관질환, 혈전색전성 질환 등의 위험성에 대해 면밀한 모니터링이 필요할 수 있음을 시사한다.

Keywords

References

  1. Hert MD, Detraux J, Winkel RV, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with anti-psychotic drugs. Nat Rev Endocrinol 2011;8:114-126.  https://doi.org/10.1038/nrendo.2011.156
  2. Hagg S, Bate A, Stahl M, spigset O. Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf 2008;31:685-694.  https://doi.org/10.2165/00002018-200831080-00005
  3. Hagg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 2002;16:765-776.  https://doi.org/10.2165/00023210-200216110-00005
  4. Masopust J, Maly R, Valis M. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry and Clinical Neurosciences 2012;66:541-552.  https://doi.org/10.1111/pcn.12001
  5. Parker C, Coupland C, Cox JH. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010;341:c4245.  https://doi.org/10.1136/bmj.c4245
  6. Kim HA, Lee JW, Kim SJ, Oh HS, Im WY, Kim JW. Second-generation antipsychotics activate platelets in antipsychotic-naive and antipsychotic-free patients with schizophrenia: a retrospective study. Int J Psychiatry Med 2020;55:105-113.  https://doi.org/10.1177/0091217419874277
  7. Kim HA, Lee JW, Kim SJ, Oh HS, Im WY, Kim JW. Clozapine administration potentiate platelet activation in patients with schizophrenia: retrospective study. Korean J Psychosomatic Med 2018;26:188-193.  https://doi.org/10.22722/KJPM.2018.26.2.188
  8. Chapman ES, Sorette M, Hetherington E, Zelmanovic D, Kling G, Dugailliez J, Pujol-Moix N, Okrongly D. A rapid, automated flow cytometric method to measure activated degranulated platelets by density determination. Thromb Haemost 2003;89:1004-1015.  https://doi.org/10.1267/THRO03061004
  9. Macey MG, Carty E, Webb L, Chapman ES, Zelmanovic D, Okrongly D, Rampton DS, Newland AC. Use of mean platelet component to measure platelet activation on the ADVIA 120 haematology system. Cytometry 1999;38:250-255.  https://doi.org/10.1002/(SICI)1097-0320(19991015)38:5<250::AID-CYTO8>3.0.CO;2-K
  10. Semiz M, Yucel H, Kavakci O, Yildirim O, Zorlu A, Yilmaz MB, Kucukdurmaz Z, Canan F. Atypical antipsychotic use is an independent predictor for the increased mean platelet volume in patients with schizophrenia: a preliminary study. J Res Med Sci 2013;18:561-566. 
  11. Jang EJ, Lee JW, Kim SJ, Oh HS, Lee Nh, Im WY, Kim JW. A retrospective study on the effect of 1-year clozapine administration on platelet activity in patients with schizophrenia or schizoaffective disorder. Korean J Psychosomatic Med 2020;28:36-41.  https://doi.org/10.22722/KJPM.2020.28.1.36
  12. Kim DS, Ryu SH, Lee JW, Kim YD, Choi YC. Mean platelet component to measure platelet activation in ischemic stroke: preliminary study. J Korean Neurol Assoc 2002;20:223-226. 
  13. Pawlus J, Holub M, Kozuch M, Dabrowska M, Dobrzycki S. Serum myeloperoxidase levels and platelet activation parameters as diagnostic and prognostic markers in the course of coronary disease. Int J Lab Hematol 201032:320-328. 
  14. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-1121.  https://doi.org/10.1016/j.ahj.2005.02.007
  15. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, Thapa-Chhetri N, Fornaro M, Gallicchio D, Collantoni E, Pigato G, Favaro A, Monaco F, Kohler C, Vancampfort D, Ward PB, Gaughran F, Carvalho AF, Stubbs B. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017;16:163-180.  https://doi.org/10.1002/wps.20420
  16. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015;14:119-136.  https://doi.org/10.1002/wps.20204
  17. Castillo-Sanchez M, Escurriola MF, Sanmartin MIF, Solntseva I, Baquero DB, Arno AG. Cardiovascular disease and mortality in people with schizophrenia or antipsychotic treatment: a cohort study in primary care. Psychiatry Res 2021 114233. Epub 2021 Oct 10. 
  18. Roberts CK and Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci 2009;84:705-712.  https://doi.org/10.1016/j.lfs.2009.02.026
  19. Santilli F, Lapenna D, La Barba S, Davi G. Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus. Free Radic Biol Med 2015;80:101-110.  https://doi.org/10.1016/j.freeradbiomed.2014.12.010
  20. Jonsson AK, Schill J, Olsson H, Spigset O, Hagg S. Venous thromboembolism during treatment with antipsychotics: a review of current evidence. CNS Drugs 2018;32:47-64.  https://doi.org/10.1007/s40263-018-0495-7
  21. Axelsson S, Hagg S, Eriksson AC, Lindahl TL, Whiss PA. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol 2007;34:775-780. https://doi.org/10.1111/j.1440-1681.2007.04650.x